Abstract | BACKGROUND: OBJECTIVE: To evaluate overall pooled study data to assess the safety profile of ustekinumab through 3 years of treatment. METHODS: Cumulative safety data were pooled from studies in 3117 ustekinumab-treated patients. RESULTS: During the placebo-controlled periods (Phase 2, PHOENIX 1, PHOENIX 2), rates of adverse events (AEs) were comparable among patients treated with placebo (50.4%), with ustekinumab 45 mg (57.6%), or with ustekinumab 90 mg (51.6%); similar findings were observed during the controlled period of the ACCEPT trial ( etanercept: 70.0%; ustekinumab 45 mg: 66.0%; and ustekinumab 90 mg: 69.2%). Rates of serious AEs (SAEs) through the controlled periods were low and comparable among all groups (1.2% to 1.9%). Through 3 years, rates of AEs per 100 patient-years of follow-up (/100 patient-yrs) (45 mg: 305.2/100 patient-yrs; 90 mg: 305.9/100 patient-yrs) and SAEs (45 mg: 6.8/100 patient-yrs; 90 mg: 8.2/100 patient-yrs) were comparable between ustekinumab doses. No cases of demyelination or tuberculosis were reported in these trials. No dose response in rates of AEs, overall infections, or SAEs was apparent through 3 years. Rates of AEs, infections, SAEs, and AEs leading to study agent discontinuation remained generally stable or decreased over time. LIMITATIONS: Controlled periods did not extend beyond 12 to 20 weeks. Only 1247 of the 3117 ustekinumab-treated patients were treated for 2 or more years. CONCLUSIONS: The safety profile of continued ustekinumab exposure through up to 3 years is favorable and consistent with previous short-term reports.
|
Authors | Mark Lebwohl, Craig Leonardi, Christopher E M Griffiths, Jörg C Prinz, Philippe O Szapary, Newman Yeilding, Cynthia Guzzo, Shu Li, Ming-Chun Hsu, Bruce Strober |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 66
Issue 5
Pg. 731-41
(May 2012)
ISSN: 1097-6787 [Electronic] United States |
PMID | 21930328
(Publication Type: Clinical Trial, Phase II, Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Immunoglobulin G
- Receptors, Tumor Necrosis Factor
- Ustekinumab
- Etanercept
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Drug-Related Side Effects and Adverse Reactions
- Etanercept
- Evaluation Studies as Topic
- Female
- Follow-Up Studies
- Humans
- Immunoglobulin G
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Psoriasis
(diagnosis, drug therapy)
- Receptors, Tumor Necrosis Factor
(therapeutic use)
- Risk Assessment
- Safety Management
- Severity of Illness Index
- Time Factors
- Treatment Outcome
- Ustekinumab
|